ESMO acknowledges Roche at 2014 congress

roche-stories-2014-09-30b-1
Dr. Giampaolo Tortora, Chair of the ESMO Translational Research Working Group and Philip Atkinson, Head of Scientific Communications for Oncology at Roche

Roche recognised in Madrid for its ongoing support for ESMO Fellowships

Roche was honoured by the European Society for Medical Oncology (ESMO) during the President’s session at this week’s ESMO congress in Madrid. A certificate marking Roche’s ongoing support of Clinical Fellowships and Translational Fellowships was presented to Philip Atkinson, Head of Scientific Communications for Oncology, by Dr. Giampaolo Tortora, Chair of the ESMO Fellowship Committee.

“Roche is proud of our association with ESMO,” Philip said. “The ESMO Fellowship Program, now celebrating its 25th anniversary, offers young oncologists the opportunity to gain research experience in outstanding European institutes and to participate in projects that have the potential to improve the quality of cancer research and the lives of patients with cancer.”

Through the Clinical Research Fellowships, young oncologists gain training in renowned European cancer centers. The fellowships also support efforts to expand professional networks through collaboration with institutions of excellence and provide the necessary support to develop clinical oncology research projects.

The Translational Research Fellowships provide training in translational research in European centers with outstanding international reputations. They also improve career development through collaboration with European institutions of excellence and provide support to develop specific high-quality translational research projects in oncology.

Roche has provided support to ESMO since the society was founded in 1975. Today, ESMO is a leading European professional medical oncology organization comprising a network of more than 15,000 oncology professionals in more than 100 countries. In addition to the Fellowship Program, Roche has provided support to the ESMO Foundation and to tumour-specific education and congresses.

“ESMO is dedicated to changing the lives of people with cancer which is why we were one of the first companies to support the Society,” Philip said. “We have the greatest respect for ESMO and fully support their multidisciplinary approach to cancer prevention, diagnosis and treatment. We also strongly support their policy initiatives to ensure that all patients with cancer have access to optimal care.”

Tags: Science